Hutchmed completes enrollment in lung cancer combination therapy trial

Hutchmed (HCM) has completed patient enrollment for its SANOVO Phase III trial, evaluating ORPATHYS (savolitinib) combined with TAGRISSO (osimertinib) as a first-line treatment for non-small cell lung cancer patients with EGFR mutations and MET overexpression. Topline results are anticipated in H2 2026, with a planned supplementary New Drug Application to China's NMPA if favorable. This progress advances a potential new therapeutic option for a specific NSCLC patient subset, leveraging a combination already approved in China for a different NSCLC indication and holding US Fast Track Designation.

Analysis

Hutchmed (HCM) has achieved a key operational milestone by completing patient enrollment for its SANOVO Phase III trial, which evaluates its MET inhibitor ORPATHYS in combination with AstraZeneca's TAGRISSO. The study targets a specific, high-need subgroup of non-small cell lung cancer (NSCLC) patients for first-line treatment, representing a significant market expansion opportunity beyond the combination's existing approval in China for a later-line setting. While this progress is fundamentally positive and validates the clinical development path, the primary value inflection point is distant, with topline results not anticipated until the second half of 2026. The program is partially de-risked by its existing Fast Track Designation in the U.S. and a prior successful Phase III study (SACHI) in a different indication, but the ultimate success hinges on the SANOVO data. The ongoing global SAFFRON Phase III trial represents a parallel catalyst path that could influence sentiment ahead of the 2026 readout.

Key Decisions for Investors

• Investors should view this as a long-term catalyst for Hutchmed, as the completion of enrollment de-risks the operational timeline but pushes the key data-driven event to H2 2026, limiting near-term impact.
• Monitor for any interim data or progress reports from the parallel global SAFFRON Phase III trial, as this could serve as a leading indicator for the combination's potential success and affect HCM's valuation before the SANOVO results.
• The investment thesis carries significant binary risk tied to the clinical outcome in 2026, so any position in HCM should be sized appropriately for a clinical-stage biotech asset with a long-duration catalyst.
• For AstraZeneca (AZN) investors, this is a minor incremental positive that supports the franchise value of TAGRISSO but is unlikely to materially impact the company's overall financial performance or stock valuation given its scale.